查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1676771

視網膜靜脈阻塞治療市場：2025-2030 年全球預測（依治療類型、年齡層、疾病類型和最終用戶）

Retinal Vein Occlusion Treatment Market by Treatment Type, Age Group, Condition Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

視網膜靜脈阻塞治療市場預計在 2024 年價值為 29.1 億美元，在 2025 年成長至 30.9 億美元，複合年成長率為 6.44%，到 2030 年將達到 42.3 億美元。

主要市場統計數據
基準年 2024 年 29.1億美元
預計 2025 年 30.9億美元
預測年份 2030 42.3億美元
複合年成長率（%） 6.44%

在醫學影像技術的進步和快速發展的治療方法的推動下，視網膜靜脈阻塞治療市場經歷了重大變化。過去幾年為突破性的研究和臨床資料鋪平了道路，正在重塑我們治療視網膜血管疾病的方式。該分析提供了對當前市場動態、新興趨勢和成長機會的全面概況。了解治療方案的歷史背景並說明新治療性介入如何影響患者結果。現在，人們正在透過將科學進步與臨床實用性無縫結合的創新解決方案來解決根深蒂固的市場挑戰。如今，患者管理越來越趨向個人化，技術進步在改善不同患者群體的治療技術方面發揮關鍵作用。此外，不斷發展的臨床方案和治療方案正在增強整體狀況。本執行摘要旨在清晰簡潔地概述行業現狀，解決不斷變化的期望、競爭壓力和監管變化，這些變化將繼續影響臨床決策和投資前景。

改變視網膜靜脈阻塞治療市場

近年來，視網膜靜脈阻塞治療領域發生了重大變化，治療方法的突破性進展重新定義了臨床實踐。從複雜的注射技術到適應性皮質類固醇製劑的開發，治療技術的不斷進步有助於提高針對視網膜疾病根本原因的精準度。同時，雷射療法與創新藥物相結合的聯合療法的療效正在臨床試驗中進行檢驗，以提高治療的安全性和有效性。監管機構也開始為新治療方法的核准提供更清晰的途徑，增強相關人員的信心並鼓勵研究資金的湧入。這些變化不僅能更有效地將實驗室發現轉化為臨床實踐，而且促進醫療設備製造商、製藥公司和執業醫師之間的合作。治療方法的快速發展反映了整個行業對個人化醫療的關注，其中明確的診斷和針對患者的治療計劃至關重要。透過接受這種變革性轉變，市場參與者將自己定位在一個動態領域的最前沿，該領域正在不斷發展以滿足老齡化和越來越注重健康的患者群體的需求。

這些不斷發展的策略凸顯了該行業致力於解決護理差距和改善長期患者治療效果的承諾。速度、創新和監管進步的結合為現有企業和新參與企業創造了前所未有的商業機會。

關鍵細分市場洞察

對市場區隔的詳細研究揭示了對於理解視網膜靜脈阻塞治療的範圍和規模至關重要的幾個關鍵方面。第一個向度是治療類型，檢視抗 VEGF 注射、皮質類固醇治療和雷射治療方式的市場。在抗 VEGF 注射類別中，治療方法進一步分為特定藥物，例如阿柏西普、Bevacizumab和雷珠單抗，每種藥物在功效和市場滲透率方面都表現出自己的特徵。另一個方面是年齡層細分，它揭示了不同人口統計的治療考慮，對 40-60 歲、60 歲以上和 40 歲以下的分析可以得出關鍵見解。此分類明確區分了視網膜分支靜脈阻塞症和視網膜中央靜脈阻塞，突顯了臨床表現和治療結果的差異。最後，透過最終用戶細分的角度了解市場動態，可以明確門診手術中心、醫院和專科診所所扮演的不同角色。這些細分見解突顯了可用的治療方法以及患者群體的異質性，使相關人員能夠更好地客製化干涉措施並有效分配資源。總體而言，細分分析不僅有助於更準確地預測市場趨勢，而且也是製定不斷發展的醫療保健策略的重要工具。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 糖尿病和高血壓等風險因素的增加意味著需要有效的治療方法
      • 醫療成本上漲促使人們投資視網膜靜脈阻塞治療方案
    • 限制因素
      • 視網膜靜脈阻塞治療費用高且報銷政策有限
    • 機會
      • 基因治療技術在視網膜靜脈阻塞長期治療的持續進展
      • 人工智慧在視網膜靜脈阻塞早期發現與個人化治療計畫的應用
    • 任務
      • 視網膜靜脈阻塞治療患者管理中的併發症
  • 市場區隔分析
    • 治療類型：抗 VEGF 注射廣泛用於治療黃斑部水腫。
    • 疾病類型：視網膜分支靜脈阻塞症發生率不斷上升，導致晚期治療需求增加
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 視網膜靜脈阻塞治療市場（依治療類型）

  • 抗 VEGF 注射劑
    • 阿柏西普
    • Bevacizumab
    • 雷珠單抗
  • 皮質類固醇治療
  • 雷射治療

第7章 視網膜靜脈阻塞治療市場（依年齡層）

  • 40-60
  • 年齡 60 歲或以上
  • 40歲以下

第 8 章視網膜靜脈阻塞治療市場（依症狀類型）

  • 視網膜分支靜脈阻塞症
  • 視網膜中央靜脈阻塞

第 9 章視網膜靜脈阻塞治療市場（依最終使用者）

  • 門診手術中心（ASC）
  • 醫院
  • 專科門診

10.美洲視網膜靜脈阻塞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區視網膜靜脈阻塞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲視網膜靜脈阻塞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie
  • Alimera Sciences, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Carl Zeiss AG
  • Fovea Pharmaceuticals SA
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Lumenis Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Suzuken Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-B570E7E0C832

The Retinal Vein Occlusion Treatment Market was valued at USD 2.91 billion in 2024 and is projected to grow to USD 3.09 billion in 2025, with a CAGR of 6.44%, reaching USD 4.23 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.91 billion
Estimated Year [2025] USD 3.09 billion
Forecast Year [2030] USD 4.23 billion
CAGR (%) 6.44%

The retinal vein occlusion treatment market has experienced significant evolution, driven by advances in medical imagery and rapidly emerging therapeutic modalities. In the past few years, research and clinical data have paved the way for breakthroughs that are reshaping how retinal vascular disorders are addressed. This analysis provides a comprehensive overview of current market dynamics along with emerging trends and opportunities for growth. The discussion navigates through the historical context of treatment options and explains the impact of novel therapeutic interventions on patient outcomes. The market's deep-rooted challenges are now being met with innovative solutions that seamlessly combine scientific advancement with clinical practicality. Today, patient management is increasingly characterized by a personalized approach, and technological advancements have played a pivotal role in refining administration techniques across diverse patient populations. Moreover, the evolution of clinical protocols and therapeutic regimes has bolstered the overall landscape. This executive summary aims to offer a clear and concise synthesis of the industry's status while addressing evolving expectations, competitive pressures, and regulatory changes that continue to shape clinical decisions and investment prospects.

Transformative Shifts in the Landscape

Recent years have witnessed transformative shifts within the retinal vein occlusion treatment landscape, as breakthroughs in therapeutic modalities now redefine clinical practices. Continuous advancements in treatment technologies-ranging from refined injection techniques to the development of adaptive corticosteroid formulations-facilitate enhanced precision in targeting the underlying causes of retinal damage. In parallel, clinical trials are increasingly validating the effectiveness of combination approaches that integrate laser therapy with innovative pharmacological agents, thereby improving both the safety and efficacy profiles of treatments. Regulatory bodies have also begun to provide clearer pathways for the approval of emerging therapies, which has bolstered confidence among stakeholders and led to an influx of research funding. These changes are not only facilitating a more efficient translation of laboratory findings into clinical solutions but are also encouraging collaborations among medical device manufacturers, pharmaceutical companies, and practitioners. The swift evolution in treatment methodologies reflects an industry-wide focus on personalized medicine, where diagnostic clarity and patient-specific treatment plans are paramount. By embracing these transformative shifts, market players are positioning themselves at the forefront of a dynamic space that continuously evolves to meet the needs of an aging and increasingly health-conscious patient demographic.

These evolving strategies underscore the commitment of the industry to address gaps in care and improve long-term patient outcomes. It is a landscape where speed, innovation, and regulated progress converge to create unprecedented opportunities for both incumbents and newer entrants.

Key Segmentation Insights

An in-depth study of the market's segmentation reveals several critical dimensions that are vital for understanding the scope and scale of retinal vein occlusion treatment. The first dimension examines treatment type, where the market is studied across anti-VEGF injection, corticosteroid treatment, and laser therapy modalities. Within the anti-VEGF injection category, therapies are further delineated into specific drugs such as Aflibercept, Bevacizumab, and Ranibizumab, each presenting its own distinct profile in terms of efficacy and market penetration. In another dimension, age group segmentation sheds light on treatment considerations across varying demographics, with key insights emerging from analysis among individuals aged between 40-60, those above 60, and even those below 40. Thirdly, the segmentation based on condition types is crucial; the classification distinctly separates branch retinal vein occlusion from central retinal vein occlusion, highlighting differences in clinical presentation and treatment outcomes. Lastly, understanding market dynamics through the lens of end user segmentation provides clarity regarding the varied roles played by ambulatory surgical centers, hospitals, and specialty clinics. These segmentation insights collectively emphasize the heterogeneity of the patient population as well as the therapeutic approaches available, situating stakeholders to better tailor interventions and allocate resources effectively. Overall, the segmentation analysis not only enhances predictive accuracy for market trends but also serves as a critical tool for strategy formulation within this evolving healthcare landscape.

Based on Treatment Type, market is studied across Anti-VEGF Injection, Corticosteroid Treatment, and Laser Therapy. The Anti-VEGF Injection is further studied across Aflibercept, Bevacizumab, and Ranibizumab.

Based on Age Group, market is studied across 40-60, Above 60, and Below 40.

Based on Condition Type, market is studied across Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion.

Based on End User, market is studied across Ambulatory Surgical Centers (ASCs), Hospitals, and Specialty Clinics.

Key Regional Insights

A regional analysis uncovers significant variances in market dynamics across key geographies. Insights drawn from the Americas reveal thriving ecosystems bolstered by robust healthcare systems and sustained investments in ophthalmological research, positioning the area as a leader in clinical innovations. In regions spanning Europe, the Middle East, and Africa, regulatory frameworks and collaborative initiatives among public and private sectors drive consistent progress in treatment uptake and research. Meanwhile, the Asia-Pacific region is characterized by accelerating advancements in technology and a rapidly expanding patient base, which in turn fuels higher demand for affordable and effective treatment options. Across these regions, trends in healthcare expenditure and patient-centric innovations have laid the groundwork for exponential growth in clinical services, while demographic shifts and an increasing prevalence of chronic conditions further underscore the significance of these findings. The analysis highlights that each geographical zone brings unique perspectives and challenges, yet all are aligned around the central goal of improving clinical outcomes through state-of-the-art therapeutic interventions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

An examination of the competitive landscape identifies a cohort of prominent companies that are at the forefront of advancing retinal vein occlusion treatments. Leading innovators such as AbbVie, Alimera Sciences, Inc., Bayer AG, and Bristol-Myers Squibb Company have been actively engaged in research-driven advancements that shape market strategies and therapeutic outcomes. These industry players are complemented by other significant contributors including Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., and GlaxoSmithKline plc, each bringing specialized expertise that reinforces market progress. Companies like IRIDEX Corporation and Johnson & Johnson Services, Inc. have leveraged technological advancements to streamline treatment protocols, while Lumenis Ltd. and Novartis AG continue to drive innovation through precision-based methodologies. Further, the contributions of Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co., Ltd., and Teva Pharmaceutical Industries Ltd. ensure a competitive balance. Their continued focus on product quality, clinical safety, and global outreach creates a landscape that is dynamic, competitive, and ripe for new innovations. This collective focus on research, strategic partnerships, and robust product pipelines is central to understanding the current market structure and anticipating future developments in treatment modalities.

The report delves into recent significant developments in the Retinal Vein Occlusion Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Alimera Sciences, Inc., Bayer AG, Bristol-Myers Squibb Company, Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., GlaxoSmithKline plc, IRIDEX Corporation, Johnson & Johnson Services, Inc., Lumenis Ltd., Novartis AG, Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co., Ltd., and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders must adopt agile and forward-thinking strategies that address both current challenges and future opportunities in retinal vein occlusion treatment. Emphasis should be placed on investing in innovation and integrating advanced therapeutic techniques, particularly in the realm of anti-VEGF injections and laser therapy enhancements, while remaining vigilant about the evolving competitive landscape. Leaders are encouraged to foster collaborations across research institutions and clinical networks to leverage emerging data for more effective patient outcomes. A strategic focus on tailoring treatment approaches to distinct patient segments, with an acute understanding of age-based nuances and specific condition types, lies at the heart of optimizing clinical efficacy. Furthermore, prioritizing investments in technology infrastructure is crucial to sustain competitive advantage in a market that rapidly evolves due to digital and data-driven healthcare innovations. Comprehensive commercial strategies should also incorporate risk assessment, regulatory compliance, and marketing initiatives that resonate with diverse end users including hospitals, ambulatory centers, and specialty clinics. Proactive engagement with key opinion leaders and incorporation of real-world evidence into decision-making processes can further enhance market positioning. Ultimately, a balance between clinical excellence and business agility is essential for preserving market leadership while adapting to emerging clinical trends and patient demands.

Conclusion: Strategic Considerations for the Future

The evolution of retinal vein occlusion treatment underscores a fundamental shift toward precision, patient-centric approaches, and innovation-driven growth. Advancements in therapeutic modalities, coupled with a nuanced understanding of market segmentation and regional trends, are defining the framework of this dynamic market. Key insights into treatment types, patient demographics, clinical conditions, and operational channels not only enhance the strategic positioning of industry players but also foster a competitive environment that incentivizes continuous improvement. As we look to the future, embracing technological progress and maintaining a clear focus on clinical excellence will be paramount in achieving sustained success. Stakeholders must therefore harness emerging insights, collaborative frameworks, and regulatory progress to drive forward innovation and operational efficiency in this ever-evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of risk factors such as diabetes and hypertension necessitating effective therapies
      • 5.1.1.2. Rising healthcare expenditure encouraging investment in retinal vein occlusion treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with retinal vein occlusion treatment & limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advances in gene therapy techniques for long-term management of retinal vein occlusion
      • 5.1.3.2. Adoption of artificial intelligence in early detection and personalized treatment plans for retinal vein occlusion
    • 5.1.4. Challenges
      • 5.1.4.1. Comorbidities complication in patient management for retinal vein occlusion treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Wide adoption of anti-VEGF injections to manage macular edema
    • 5.2.2. Condition Type: Growing prevalence of branch retinal vein occlusion boosting demand for advanced treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinal Vein Occlusion Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Anti-VEGF Injection
    • 6.2.1. Aflibercept
    • 6.2.2. Bevacizumab
    • 6.2.3. Ranibizumab
  • 6.3. Corticosteroid Treatment
  • 6.4. Laser Therapy

7. Retinal Vein Occlusion Treatment Market, by Age Group

  • 7.1. Introduction
  • 7.2. 40-60
  • 7.3. Above 60
  • 7.4. Below 40

8. Retinal Vein Occlusion Treatment Market, by Condition Type

  • 8.1. Introduction
  • 8.2. Branch Retinal Vein Occlusion
  • 8.3. Central Retinal Vein Occlusion

9. Retinal Vein Occlusion Treatment Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers (ASCs)
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Retinal Vein Occlusion Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Retinal Vein Occlusion Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Retinal Vein Occlusion Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. European Commission approves groundbreaking Vabysmo treatment, revolutionizing retinal vein occlusion care across the EU
    • 13.3.2. Health Canada approves Vabysmo for retinal vein occlusion
    • 13.3.3. Chugai's Vabysmo secures approval as the first bispecific antibody for retinal vein occlusion treatment in Japan
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Alimera Sciences, Inc.
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Carl Zeiss AG
  • 6. Fovea Pharmaceuticals SA
  • 7. Genentech, Inc.
  • 8. GlaxoSmithKline plc
  • 9. IRIDEX Corporation
  • 10. Johnson & Johnson Services, Inc.
  • 11. Lumenis Ltd.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Ranbaxy Pharmaceuticals Inc.
  • 15. Regeneron Pharmaceuticals, Inc.
  • 16. Sanofi S.A.
  • 17. Suzuken Co., Ltd.
  • 18. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. RETINAL VEIN OCCLUSION TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. RETINAL VEIN OCCLUSION TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. RETINAL VEIN OCCLUSION TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. RETINAL VEIN OCCLUSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. RETINAL VEIN OCCLUSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RETINAL VEIN OCCLUSION TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINAL VEIN OCCLUSION TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CORTICOSTEROID TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY 40-60, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ABOVE 60, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BELOW 40, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. RETINAL VEIN OCCLUSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 236. RETINAL VEIN OCCLUSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024